Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: Sadif Analytics Prime
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

R&I affirms Dainippon Sumitomo Pharma’s rating at "A" and rating outlook stable


Tuesday, 25 Mar 2014 02:00am EDT 

Dainippon Sumitomo Pharma Co Ltd:Rating and Investment Information, Inc. (R&I) has affirmed the rating on the company at "A".The rating outlook is stable. 

Company Quote

1280.0
28.0 +2.24%
24 Oct 2014